Literature DB >> 23997508

Statistics for surgeons - understanding survival analysis.

Girdhar Gopal Agarwal1.   

Abstract

Survival data stand out as a special statistical field. This paper tries to describe what survival data is and what makes it so special. Survival data concerns times to some events. A key point is the successive observation of time, which on the one hand leads to sometimes not being observed so that all that is known is that they exceed some given times (censoring), and on the other hand implies that predictions regarding the future course should be conditional on the present status (truncation). In the simplest case, this condition is that the individual is alive. The successive conditioning makes the hazard function, which describes the probability of an event happening during a short interval given that the individual is alive today, the most relevant concept. Here we discuss parametric as well as non-parametric methods. Examples are presented in a way that can be followed without the help of computers.

Keywords:  Censored data; Hazard function; Kaplan-Meier estimate; Logrank test; Survivor function

Year:  2012        PMID: 23997508      PMCID: PMC3444589          DOI: 10.1007/s13193-012-0149-z

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  8 in total

1.  The relative survival rate: a statistical methodology.

Authors:  F EDERER; L M AXTELL; S J CUTLER
Journal:  Natl Cancer Inst Monogr       Date:  1961-09

Review 2.  Statistical methods for the identification and use of prognostic factors.

Authors:  P Armitage; E A Gehan
Journal:  Int J Cancer       Date:  1974-01-15       Impact factor: 7.396

3.  Designs for group sequential tests.

Authors:  T R Fleming; D P Harrington; P C O'Brien
Journal:  Control Clin Trials       Date:  1984-12

4.  Long term survival analysis: the curability of breast cancer.

Authors:  S J Pocock; S M Gore; G R Kerr
Journal:  Stat Med       Date:  1982 Apr-Jun       Impact factor: 2.373

5.  Cancer-specific beliefs and survival: a population-based study of African-American and White breast cancer patients.

Authors:  Hosanna Soler-Vila; Stanislav V Kasl; Beth A Jones
Journal:  Cancer Causes Control       Date:  2005-03       Impact factor: 2.506

6.  Combination chemotherapy as an adjuvant treatment in operable breast cancer.

Authors:  G Bonadonna; E Brusamolino; P Valagussa; A Rossi; L Brugnatelli; C Brambilla; M De Lena; G Tancini; E Bajetta; R Musumeci; U Veronesi
Journal:  N Engl J Med       Date:  1976-02-19       Impact factor: 91.245

7.  Censoring in an epidemic with an application to hemophilia-associated AIDS.

Authors:  R Brookmeyer; J J Goedert
Journal:  Biometrics       Date:  1989-03       Impact factor: 2.571

8.  Adjuvant chemoimmunotherapy after regional lymphadenectomy for malignant melanoma.

Authors:  E A Abdi; J Hanson; T A McPherson
Journal:  Am J Clin Oncol       Date:  1987-04       Impact factor: 2.339

  8 in total
  2 in total

1.  Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21-gene recurrence score of 26-30.

Authors:  Jing Yu; Jiayi Wu; Ou Huang; Jianrong He; Li Zhu; Weiguo Chen; Yafen Li; Xiaosong Chen; Kunwei Shen
Journal:  Oncol Lett       Date:  2020-06-16       Impact factor: 2.967

2.  Converging or Crossing Curves: Untie the Gordian Knot or Cut it? Appropriate Statistics for Non-Proportional Hazards in Decitabine DACO-016 Study (AML).

Authors:  Jörg Tomeczkowski; Ansgar Lange; Andreas Güntert; Pushpike Thilakarathne; Joris Diels; Liang Xiu; Peter De Porre; Christoph Tapprich
Journal:  Adv Ther       Date:  2015-09-14       Impact factor: 3.845

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.